Clinical trial · Interventional
Letrozole and Cabergoline Versus Letrozole Alone in Ovulation Induction
Letrozole and Cabergoline Versus Letrozole Alone in Ovulation Induction Among PCOS Patients in Assiut Governorate
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Polycystic Ovarian Syndrome (PCOS) is the most common endocrine disorders in women of reproductive age. According to the World Health Organization (WHO) estimation revealed over 116 million women (3.4%) are affected by PCOS worldwide. Owing to the intricacy of this condition, various sets of diagnostic criteria have been initiated for the confirmation of PCOS which are: National Institute of Health, Rotterdam's Criteria, Androgen Excess and PCOS society. The prevalence of PCOS is estimated at about 4 to 21 % when it is diagnosed according to the Rotterdam criteria accounting for 75% of cases with anovulatory infertility.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| PCOS (Polycystic Ovary Syndrome) | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Letrozole tablets | Drug | Letrozole | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Group A (Letrozole with cabergoline)
- description
- About 50 of infertile female with PCOs whom received Letrozole, 5mg daily for 5 days, from day 3 of the cycle up to 7th day for 3 cycles in addition to cabergoline, 0.5 mg weekly for 12 weeks.
- interventionNames
- Drug: Letrozole tablets
- type
- ACTIVE_COMPARATOR
- label
- Group B (Letrozole only)
- description
- About 50 of infertile female with PCOs whom received Letrozole only, 5mg daily for 5 days, from day 3 of the cycle up to 7th day for 3 cycles.
- interventionNames
- Drug: Letrozole tablets
Primary outcomes (1)
- measure
- Identification of Ovulation
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 40 Years
Show eligibility criteria text
Inclusion Criteria:
* Women diagnosed with PCOS according to Rotterdam criteria (Rotterdam, 2004) as:
1. Menstrual anomalies like amenorrhea (no cycles in the past 6 months), oligomenorrhoea (cycles lasting longer than 35 days), or long cycles.
2. Clinical and/or biochemical hyperandrogenism.
3. Ultrasound (USG) appearance of polycystic ovaries (multiple cysts \>12 in number of 2-9 mm size).
Exclusion Criteria:
* Patient with liver and kidney disease.
* Congenital adrenal hyperplasia.
* Hypothalamic or pituitary cause of amenorrhea.
* Primary hyperprolactinemia.References
Publications (0)
Data not yet available